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Background: The purpose of this study was to examine the effect of proton pump inhibitors 
(PPI) on the antiplatelet activity of clopidogrel in a consecutive series of Chinese patients after 
they had received coronary stents.
Methods: A sample of 51 consecutive Chinese patients treated with coronary stents and taking 
PPI and clopidogrel for more than 30 days were enrolled in this study. Mean values for platelet 
residual units and percentage inhibition before PPI (+PPI) and 14 days after discontinuation of 
PPI (-PPI) were compared using the paired t-test.
Results: There was no effect of concomitant use of esomeprazole and clopidogrel or omeprazole 
and clopidogrel on the inhibition assay, but platelet residual units and percentage inhibition 
showed statistically significant improvement after stopping lansoprazole in Chinese patients 
who were on chronic clopidogrel therapy. Clopidogrel resistance existed more frequently in the 
Chinese-American population examined, and was as high as 68% (+PPI) to 73% (-PPI).
Conclusion: The clopidogrel resistance found is cause for concern, although its relationship with 
clinical events is currently unknown in this population. Further study with other thienopyridines 
or genetic variant analysis is suggested.
Keywords: proton pump inhibitors, clopidogrel resistance, Chinese population, percutaneous 
coronary intervention
Introduction
Stent thrombosis remains a serious complication of coronary artery stent implantation. 
Despite routine dual antiplatelet therapy with acetylsalicylic acid and thienopyridines, 
the incidence of stent thrombosis persists at a rate of 0.5%–2%.1 Several factors have 
been associated with an increased risk of stent thrombosis, ie, long and multiple stents, 
stent malapposition, residual dissection, lack of dual antiplatelet drugs, and platelet 
polymorphism.2,3 Resistance to acetylsalicylic acid and clopidogrel has been suggested 
as a possible cause of stent thrombosis, but conclusive data are lacking. Although low 
responders to clopidogrel had a significantly higher risk of major cardiovascular events 
(22.7% versus 5.6%), wide interindividual variability in platelet responsiveness to 
clopidogrel among individuals remains a topic of intense debate.4,5
Proton pump inhibitors (PPI) have been advocated to lower the gastrointestinal 
  bleeding risk in patients receiving the combination of aspirin and clopidogrel.6,7   However, 
recent data suggest that PPI may lower the antiplatelet effect of clopidogrel in patients 
undergoing coronary stent implantation.8 Angiolillo et al suggested in their recent study 
that a metabolic drug–drug interaction exists between clopidogrel and omeprazole but 
not between clopidogrel and pantoprazole.9 This controversial drug interaction could be Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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important among Chinese-American patients, who have an 
increased ulcer bleeding risk and are known to have the most 
frequent cytochrome P450 (CYP) 2C19 loss-of-function muta-
tion, which is important for clopidogrel metabolism.10 In this 
study, we examined the effect of PPI on the antiplatelet activity 
of clopidogrel in a consecutive series of Chinese patients after 
they received coronary stents.
Methods
Fifty-one consecutive immigrant Chinese patients treated 
with coronary stenting and PPI were enrolled in this 
  prospective study. Patients were included if they had 
been on chronic (.30 days) clopidogrel therapy. Patients 
with active   gastrointestinal bleeding or history of massive 
  gastrointestinal bleeding requiring blood transfusion were 
excluded from the trial. Other exclusion criteria included 
malignancy, oral coumadin, or platelet count ,100 × 109/L. 
After patients gave informed consent, platelet inhibition 
assays before (+PPI) and 14 days after discontinuation of 
PPI (-PPI) were obtained using the VerifyNow® P2Y12 
(Accumetrics Inc, San Diego, CA) assay.11
Platelet function assay
VerifyNow was approved by the US Food and Drug Admin-
istration in 2005. The VerifyNow P2Y12 assay is a whole 
blood, point-of-care assay, which consists of an instrument 
and a single-use assay device containing the biochemical 
reagents required to perform the assay. A venous blood sample 
was collected in 3.2% citrate with a loose tourniquet through 
a short venous catheter inserted into a forearm vein. Platelet 
function testing 4–6 hours after the last dose of clopidogrel 
was performed. A multiple syringe technique was used and 
the first 2 mL of blood was discarded. Percentage inhibition 
of platelets and the P2Y12 reactivity unit were measured in 
order to assess responsiveness to clopidogrel. In addition 
to 20 µm adenosine diphosphate, 22 nM prostaglandin E1 
is incorporated into the VerifyNow P2Y12 assay device to 
  suppress intracellular free calcium levels and thereby reduce 
the contribution from adenosine diphosphate binding to 
P2Y12 receptors. In a separate channel in which iso-TRAP is 
used as an agonist, a baseline value for platelet function was 
obtained. The VerifyNow P2Y12 assay reports patient results 
as P2Y12 reaction units, inhibition, and the baseline value in 
less than five minutes. Percentage inhibition was calculated 
as (P2Y12 reactivity units/baseline) × 100. The hospital 
institutional review board approved this research. The study 
data are   presented as means ± standard deviation, counts, or 
percentages if not otherwise stated. Mean values of continuous 
variables were compared using the one-tailed paired t-test. 
P values , 0.05 were considered statistically significant.
Results
Fifty-one patients were enrolled into this study. Seven patients 
dropped out (three continued to take their PPI, one declined 
the second blood draw, one was not on a PPI at all, one had 
severe anemia after day 1, and one had severe gastritis). A total 
of 96 blood samples and 44 patients were analyzed in this 
study (Table 1) after excluding the initial seven samples of 
first blood drawn for patients who dropped out.
There was no statistically significant difference 
  overall between the three different +PPI versus -PPI 
  samplings for percentage inhibition (19.95% ± 9.78% 
versus 20.88% ± 15.70%, P = 0.30) and P2Y12 reactivity 
units (267 ± 65.4 versus 275 ± 70.1, P = 0.15, Figures 1A 
and 1B). In subgroup analyses of the three different PPI, 
there were no differences in percentage inhibition or P2Y12 
reactivity units for concomitant usage of esomeprazole and 
clopidogrel and omeprazole and clopidogrel. However, 
there was a statistically significant improvement in platelet 
inhibition by clopidogrel 14 days after cessation of lanso-
prazole (P = 0.013 for P2Y12 reactivity units and P = 0.04 
for percentage inhibition, Table 2). Subgroup analyses in 
terms of diabetes, age, gender, and smoking also did not 
show any significant differences in percentage inhibition or 
P2Y12 reactivity units (Table 3). When a P2Y12 reactivity 
unit level $ 235 was used for the cutoff according to Price 
et al,12 68% of the +PPI samples and 73% of -PPI samples 
were nonresponders. When ,40% inhibition was consid-
ered as a poor response to clopidogrel by Cambo et al,13 
84% of +PPI and 91% of -PPI patients were nonresponders 
(Figures 2A and 2B).
Table 1 Patient demographics
n 44
Age (years) 54–86 (mean 73)
Male 25 (57%)
Smoking 10 (23%)
Diabetes mellitus 16 (37%)
Hypertension 38 (87%)
Hyperlipidemia 33 (75%)
History of MI 6 (14%)
History of CABG 5 (11%)
History of PTCA 26 (59%)
ESRD 5 (11%)
Taking aspirin 29 (67%)
Taking statins 25 (57%)
Abbreviations: MI, myocardial infarction; CABG, coronary artery bypass graft; 
PTCA,  percutaneous  transluminal  coronary  angioplasty;  ESRD,  end-stage  renal 
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Table 2 P2Y12 reaction units and percentage inhibition for different proton pump inhibitors
PPI n Mean PRU D1 ± SD Mean PRU D14 ± SD P value Mean % Inh D1 ± SD Mean % Inh D14 ± SD P value
Esomeprazole 27 273.52 ± 58 270.85 ± 52 0.35 17.18 ± 13 20.34 ± 13 0.08
Omeprazole 11 247.2 ± 63 260.3 ± 107 0.26 26 ± 17 27.7 ± 23 0.39
Lansoprazole 6 273.14 ± 101 317 ± 91 0.01 22 ± 20.5 13.14 ± 15.46 0.04
Abbreviations: PRU, P2Y12 reaction units; % Inh, percent inhibition; SD, standard deviation.
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Figure 1 (A) Mean percent inhibition of clopidogrel between day 1 and day 14. 
(B) Mean P2Y12 reaction units between day 1 and day 14.
Abbreviation: PRU, P2Y12 reaction unit.
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Discussion
Our small, single-center study suggests that there was no 
effect of concomitant use of esomeprazole and clopidogrel 
and omeprazole and clopidogrel on the inhibition assay in 
our Chinese study population. Furthermore, as previously 
described, P2Y12 reactivity units and percentage inhibition 
showed a statistically significant improvement after stop-
ping lansoprazole in patients who were on chronic clopi-
dogrel therapy. However, there were only six patients in the 
lansoprazole group. Interestingly, clopidogrel resistance 
existed more frequently in the Chinese-American population 
examined, being as high as 68% (+PPI) to 73% (-PPI). This 
is cause for concern, although the correlation with clinical 
events is currently unknown in this population.
Clopidogrel is a prodrug, which requires conversion by 
the liver primarily via CYP3A4 and CYP2C19 to an active 
metabolite, which irreversibly binds to the platelet   adenosine 
diphosphate receptor.14 CYP2C19 metabolic activity is highly 
variable among patients because of genetic variation. Several 
gene variants associated with reduced or absent CYP2C19 
activity exist, although the CYP2C19*2 allele accounts for 
more than 90% of cases of poor metabolism.15 Metabolic 
activation by CYP2C19 has emerged as a crucial determinant 
of the pharmacodynamics and clinical efficacy of clopidogrel. 
Lack of metabolism has contributed to a higher rate of recur-
rent cardiovascular events compared with noncarriers.16
PPI, notably omeprazole and lansoprazole, are strong 
inhibitors of CYP2C19 activities. Ex vivo biological   studies 
have suggested that coadministration of omeprazole or 
lansoprazole may decrease the antiplatelet effect of clopi-
dogrel, whereas this interaction was not reported with other 
PPI, such as pantoprazole or esomeprazole.17 Our data also 
suggest that lansoprazole decreases the antiplatelet effect 
of clopidogrel, but that omeprazole and clopidogrel do not. 
Recent studies have questioned the validity of actual interac-
tions between clopidogrel and PPI, whether this interaction 
is the pH-mediated effect of gastrointestinal absorption as a 
class effect, or a CYP2C19-mediated effect of metabolism 
with clopidogrel as the victim and PPI as the perpetrator.18 
Studies suggested that some PPI may affect the conversion 
of clopidogrel to its active metabolite by possible inhibition 
of CYP2C19, but the exact mechanism of this drug–drug 
interaction remains to be determined. There is also specula-
tion as to whether the use of PPI reduces the clinical efficacy 
of clopidogrel. Several population-targeted studies have 
reported that use of PPI increases the risk for cardiac events 
in clopidogrel-treated patients.19 Whether a differential effect 
exists between individual PPI was unclear. It was noted in sev-
eral editorials that the lack of risk adjustment was a limitation 
of several of these early studies.20 For this reason, regulatory 
authorities have indicated the need for further investigations 
regarding this important health care issue.
In coronary patients who carry the genetic variant 
  associated with a loss of function of the CYP2C19 enzyme, 
the risk of stent thrombosis on clopidogrel treatment is 
3–6-fold higher.21,22 However, the influence and magnitude 
of risk of the CYP2C19 genotype have been inconsistent 
among studies.23 A recent genome-wide association study 
has shown that common variants in the CYP2C19 gene 
locus are the dominant explanation for variance in the Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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antiplatelet response to clopidogrel.24 Among the variants 
of CYP2C19, the *2 and *3 variants are the most common 
loss-of-function alleles. The presence of the CYP2C19*3 
allele is very rare in Caucasians and very common in East 
Asians, especially in Chinese populations (7%–10%).25–30 
In a study by Luo et al, the presence of the CYP2C19*2 
(loss-of-function) allele in different populations is as follows: 
Mexican Americans (9.7%), Caucasians (12.7%), African-
Americans (18.2%), and Chinese (29%).31 Wang et al showed 
clopidogrel resistance in 16.8% of their post-percutaneous 
coronary intervention population, with 16.9% of this group 
suffering composite thrombotic events versus 6.2% of the 
clopidogrel-responsive group.32 The consequences of these 
variants include a significantly increased risk for bleeding, 
myocardial infarction, stent thrombosis, and death. With 
stent thrombosis rates in carriers of CYP2C19 as high as 
11%, mortality associated with such events is close to 50%. 
There is a nearly two-fold increase in the risk of bleeding in 
CYP2C19*17 gain-of-function mutation carriers because of 
increased clopidogrel activation. We should thus take a more 
vigilant approach in these patients to prevent catastrophic 
outcomes.33 Although patients with diabetes mellitus are 
reported to be decreased metabolizers of clopidogrel, we 
did not find any statistically significant difference in P2Y12 
reactivity units and percentage inhibition between diabetic 
and nondiabetic patients.34
Individualized dual antiplatelet agents may help overcome 
some of the shortcomings of hyporesponders. Investiga-
tors have recently demonstrated an eight-fold reduction in 
stent thrombosis by administering additional loading doses 
of clopidogrel in patients with a poor baseline response.35 
Analyses limited to data from clopidogrel-treated patients 
have shown a relative risk of major cardiovascular events that 
was increased by a factor of 1.53–3.69 among carriers of loss-
of-function alleles as compared with noncarriers, including a 
1.7–2.4-fold increase in risk of subacute stent thrombosis.36 
On the basis of these findings and related pharmacokinetic 
and pharmacodynamic data (Clinicaltrials.gov number, 
NCT01123824), the Food and Drug Administration has 
issued a black box warning about reduced effectiveness 
of clopidogrel in patients who are carriers of two loss-of 
function alleles and has suggested that carriers of these 
alleles should receive a higher dose of clopidogrel or an 
alternative antiplatelet agent. In some instances, up to 
2400 mg was required to achieve optimal antiplatelet effects. 
In addition, recent data suggested that doubling of the clopi-
dogrel maintenance dose in the initial implantation period 
could confer significant benefit.   Furthermore, prasugrel, a 
newly approved thienopyridine with more rapid and greater 
inhibition of platelets, has now emerged as a viable option. 
Another possible option in the near future will be ticagrelor, 
the first of a new class of orally active nonthienopyridine 
agents, which has a reversible antiplatelet effect and does 
not require activation. Furthermore, this agent has a faster 
Table 3 Subgroup analyses for P2Y12 reaction units and percentage inhibition
n Mean PRU D1 Mean PRU D14 P value Mean % Inh D1 Mean % Inh D14 P value
Diabetes + 
-
17 281.23 304.94 0.18 18.47 17.17 0.4
27 258.81 257.44 0.46 20.89 23.22 0.29
Smoking + 
-
11 264.09 276.27 0.37 24.36 23.36 0.45
33 268.6 275.63 0.32 18.48 20.06 0.33
Age # 73 
. 73
24 263.1 262.5 0.48 19.25 20.6 0.38
20 271.12 286.87 0.25 20.54 21.12 0.45
Abbreviations: PRU, P2Y12 reaction unit; % Inh, percentage inhibition.
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Figure 2 (A) Number of patients responding to clopidogrel using mean percentage 
inhibition , 40%. (B) Number of patients responding to clopidogrel using mean 
P2Y12 reaction units $ 235.
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and more consistent antiplatelet effect compared with current 
standard treatment.22
Critics of CYP2C19 suggest that the predictive capaci-
ties of these tests are modest compared with genotyping and, 
  notably, do not foretell a patient’s risk for bleeding. Other prob-
lems with platelet function tests include results that are incon-
sistent and dynamic when assessed at different time points in 
the same patient, lack of a standard definition of suboptimal 
platelet response, and disagreement on the best method for 
measuring platelet function. Hence, current   evidence supports 
the prototype of individualized medical therapy in the future. 
Translational medicine has transformed the current practice 
of medicine to specific personalized algorithms to provide 
  optimal medical therapy. Further study of other thienopyridines 
or genetic variant analysis is suggested.
The limitations of our study are as follows. First, it was 
conducted at a single center and had a relatively small sample 
size, although was larger than some others reported in the 
literature. Second, the PPI 14-day washout period may not be 
enough for some patients. Third, clinical outcomes were not 
assessed. Alternative methods of platelet function testing, such 
as vasodilatation-stimulated phosphoprotein phosphorylation, 
should be used to validate this single test result. Nonetheless, 
this study sheds some light on hyporesponsiveness to clopi-
dogrel in Chinese-American patients on chronic therapy.
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